Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax (2022 - 2026)

Centessa Pharmaceuticals has reported Long-Term Deferred Tax over the past 4 years, most recently at $24.8 million for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 6.8% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.8 million through Dec 2025, down 6.8% year-over-year, with the annual reading at $24.8 million for FY2025, 6.8% down from the prior year.
  • Long-Term Deferred Tax was $24.8 million for Q4 2025 at Centessa Pharmaceuticals, down from $25.0 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $29.6 million in Q4 2023 and troughed at $3.5 million in Q4 2022.
  • The 4-year median for Long-Term Deferred Tax is $26.7 million (2023), against an average of $25.2 million.
  • Year-over-year, Long-Term Deferred Tax skyrocketed 744.16% in 2023 and then decreased 11.27% in 2025.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $3.5 million in 2022, then skyrocketed by 744.16% to $29.6 million in 2023, then dropped by 10.32% to $26.6 million in 2024, then dropped by 6.8% to $24.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Long-Term Deferred Tax are $24.8 million (Q4 2025), $25.0 million (Q3 2025), and $25.4 million (Q2 2025).